Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer (Q37844487)

24 August 2017

1 reference

title

Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer (English)

1 reference

24 August 2017

Ewa Malgorzata Michalak

series ordinal

1

1 reference

PubMed ID

21331759

24 August 2017

Jos Jonkers

series ordinal

2

1 reference

PubMed ID

21331759

24 August 2017

language of work or name

1 reference

18 February 2011

1 reference

Journal of Mammary Gland Biology and Neoplasia

24 August 2017

1 reference

24 August 2017

16

1 reference

24 August 2017

1

1 reference

24 August 2017

41-50

1 reference

https://scigraph.springernature.com/pub.10.1007/s10911-011-9199-z

24 August 2017

0 references

cites work

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Founder mutations in BRCA1 and BRCA2 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

The role of BRCA1 in transcriptional regulation and cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

BRCA1 supports XIST RNA concentration on the inactive X chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Supervised risk predictor of breast cancer based on intrinsic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

The resurgence of platinum-based cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

The mighty mouse: genetically engineered mouse models in cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Cross-species oncogenomics in cancer gene identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

A new model of patient tumor-derived breast cancer xenografts for preclinical assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Preclinical mouse models for BRCA1-associated breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

A mouse model of basal-like breast carcinoma with metaplastic elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

The ground state of embryonic stem cell self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Validated germline-competent embryonic stem cell lines from nonobese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Prevention and management of hereditary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10911-011-9199-Z

Studying drug resistance using genetically engineered mouse models for breast cancer

21 January 2018

1 reference

12 December 2020

Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts

1 reference

12 December 2020

Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors

1 reference

12 December 2020

Triple-Negative Breast Cancer

1 reference

12 December 2020

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator

1 reference

12 December 2020

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

1 reference

12 December 2020

BRCA1 and its toolbox for the maintenance of genome integrity

1 reference

12 December 2020

BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications

1 reference

12 December 2020

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations

1 reference

12 December 2020

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

1 reference

12 December 2020

Treatment options for patients with triple-negative breast cancer

1 reference

12 December 2020

Triple negative breast cancer: unmet medical needs

1 reference

12 December 2020

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

1 reference

12 December 2020

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

1 reference

12 December 2020

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

1 reference

12 December 2020

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

1 reference

12 December 2020

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors

1 reference

12 December 2020

BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells

1 reference

12 December 2020

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

1 reference

12 December 2020

Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation

1 reference

12 December 2020

Progesterone induces adult mammary stem cell expansion

1 reference

12 December 2020

Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers

1 reference

12 December 2020

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

12 December 2020

Therapeutic options for triple-negative breast cancers with defective homologous recombination

1 reference

12 December 2020

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation

1 reference

12 December 2020

Control of mammary stem cell function by steroid hormone signalling.

1 reference

12 December 2020

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

12 December 2020

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

1 reference

12 December 2020

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan

1 reference

12 December 2020

Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH

1 reference

12 December 2020

BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors

1 reference

12 December 2020

Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways

1 reference

12 December 2020

From human to mouse and back: 'tumorgraft' models surge in popularity

1 reference

12 December 2020

10.1007/S10911-011-9199-Z

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21331759